Literature DB >> 28350078

miR-28-5p promotes the development and progression of ovarian cancer through inhibition of N4BP1.

Juan Xu1, Nan Jiang1, Haijuan Shi1, Shanshan Zhao1, Shuzhong Yao1, Huimin Shen1.   

Abstract

MicroRNAs (miRNAs) play important roles in transcriptional regulation by targeting the 3'-UTR of target genes which participate in various biological processes. We aimed to investigate the potential role of miR-28-5p in the process of ovarian cancer development through regulating N4BP1. We found that the mRNA expression level of miR-28-5p was significantly increased in ovarian cancer tissues in comparison with adjacent ovarian tissues by qRT-PCR (P<0.0001). We established that miR‑28‑5p promoted the progression of ovarian cancer cell proliferation using colony forming assay and MTT assay. Wound healing assay and the migration and invasion assay showed that miR‑28‑5p accelerated the migration and invasion abilities of ovarian cancer cells. Simultaneously, we showed that miR‑28‑5p promoted ovarian cancer cell cycle, and inhibited apoptosis by flow cytometry in vitro. Furthermore, the results showed that miR‑28‑5p promoted the growth of ovarian tumor by tumor formation assay in vivo. The results of western blot analysis indicated that miR‑28‑5p promoted the protein expression level of F-actin. Western blot analysis also demonstrated that miR‑28‑5p promoted the progress of epithelial-mesenchymal transition (EMT) in ovarian carcinoma cells. In addition, we found that miR‑28‑5p downregulated N4BP1 mRNA and protein expression by qRT-PCR and western blot analysis in human ovarian cancer. Therefore, our study indicated that miR‑28‑5p promoted the progression of ovarian cancer cell cycle, proliferation, migration and invasion, inhibited apoptosis, and induced the process of EMT through inhibition of N4BP1 in vitro. Moreover, miR‑28‑5p promoted the growth of ovarian tumor in vivo.

Entities:  

Year:  2017        PMID: 28350078     DOI: 10.3892/ijo.2017.3915

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  Reduced Levels of miR-28 and miR-200a Act as Predictor Biomarkers of Aggressive Clinicopathological Characteristics in Gastric Cancer Patients.

Authors:  Farhad Jeddi; Shahriar Alipour; Nowruz Najafzadeh; Mehdi Dadashpour; Farhad Pouremamali; Mohammad Reza Sadeghi; Nasser Samadi; Narges Soozangar; Amir Mahdi Khamaneh
Journal:  Galen Med J       Date:  2019-01-25

2.  The miRNA Pull Out Assay as a Method to Validate the miR-28-5p Targets Identified in Other Tumor Contexts in Prostate Cancer.

Authors:  Milena Rizzo; Gabriele Berti; Francesco Russo; Monica Evangelista; Marco Pellegrini; Giuseppe Rainaldi
Journal:  Int J Genomics       Date:  2017-09-20       Impact factor: 2.326

3.  Clinical Significance and Prognostic Value of miR-28-5p in Colon Cancer.

Authors:  Ji-Lin Li; Ke-Zhi Li; Ming-Zhi Xie; Yan-Ping Tang; Yin-Lin Tang; Bangli Hu
Journal:  Dis Markers       Date:  2020-05-20       Impact factor: 3.434

4.  The miR-28-5p Targetome Discovery Identified SREBF2 as One of the Mediators of the miR-28-5p Tumor Suppressor Activity in Prostate Cancer Cells.

Authors:  Sofia Fazio; Gabriele Berti; Francesco Russo; Monica Evangelista; Romina D'Aurizio; Alberto Mercatanti; Marco Pellegrini; Milena Rizzo
Journal:  Cells       Date:  2020-02-03       Impact factor: 6.600

5.  hsa-MicroRNA-28-5p Inhibits Diffuse Large B-Cell Lymphoma Cell Proliferation by Downregulating 14-3-3ζ Expression.

Authors:  Shufang Yan; Yang Chen; Meihong Yang; Qian Zhang; Jiajia Ma; Bo Liu; Liuqing Yang; Xinxia Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-04       Impact factor: 2.629

6.  Effects of hsa-miR-28-5p on Adriamycin Sensitivity in Diffuse Large B-Cell Lymphoma.

Authors:  Shufang Yan; Qinyu Shang; Haipeng Zhu; Ken Chen; Xinxia Li; Hongliang Gao; Bo Liu; Mei Feng; Lixia Gao
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-13       Impact factor: 2.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.